News | January 18, 2013

GE Files Supplemental New Drug Application for Its Own Manufacturing of Optison Ultrasound Contrast

Upon approval, GE Healthcare’s Oslo facility will provide stock to the United States, becoming the only contrast media manufacturer to supply its own stock to the U.S. market

January 18, 2013 — GE Healthcare announced that it has filed a supplemental new drug application (sNDA) that will allow the company to manufacture Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), within its own facility. Optison is a contrast agent that may improve the visualization of the left ventricular border — an area of the heart that is critical to see in order to assess and diagnose certain heart diseases. Upon approval, GE Healthcare will provide supply of Optison to the U.S. market from its manufacturing facility in Oslo, becoming the only contrast media manufacturer to supply its own stock for the United States.

Optison is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricle and to improve delineation of the left ventricular endocardial borders. Optison is not for use in patients with known or suspected: (1) Right-to-left, bi-directional, or transient right-to-left cardiac shunts, or (2) hypersensitivity to perflutren, blood, blood products or albumin. It should not be administered by intra-arterial injection. As for all ultrasound contrast agents, Optison has a boxed warning indicating that serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration. Healthcare professionals should assess all patients for the presence of any condition that precludes Optison administration and always have resuscitation equipment and trained personnel readily available.

Optison remains an important diagnostic option for patients with suboptimal echocardiograms. Additionally, Optison offers a unique, convenient value to clinicians and patients: It is stable at room temperature for up to 24 hours and takes less than 60 seconds to prepare, allowing for quick access to contrast in hospital settings like the cardiac lab or emergency room.

Optison vials do not contain preservative and are for single patient use only. Healthcare professionals should follow labeled instructions for product handling and use and discard unused product properly.

The most frequently reported adverse reactions following clinical trial use of Optison were headache, nausea and/or vomiting, warm sensation or flushing and dizziness. Cardiac arrests and other serious but non-fatal adverse reactions were uncommonly reported post-marketing. Most of these uncommon reactions included cardiopulmonary symptoms and signs such as cardiac or respiratory arrest, hypotension, supraventricular and ventricular arrhythmias, respiratory distress or decreased oxygenation. Reports also identified neurologic reactions (loss of consciousness or convulsions) as well as anaphylactoid reactions.

For more information: www.gehealthcare.com

Related Content

EchoGo uses artificial intelligence (AI) to calculate cardiac ultrasound left ventricular ejection fraction (EF), the most frequently used measurement of heart function, left ventricular volumes (LV) and, for the first time for an AI application, automated cardiac strain.

EchoGo uses artificial intelligence (AI) to calculate cardiac ultrasound left ventricular ejection fraction (EF), the most frequently used measurement of heart function, left ventricular volumes (LV) and, for the first time for an AI application, automated cardiac strain.

News | Cardiovascular Ultrasound | November 14, 2019
November 14, 2019 — Ultromics has received 510(k) clearance from the U.S.

Guerbet presented its Contrast&Care injection management solution at ECR 2018

News | Contrast Media | November 13, 2019
November 13, 2019 – Guerbet, a global specialist in...
Mindray announced its partnership with Cincinnati Children's Hospital Medical Center, one of the top children's hospitals in the United States
News | Ultrasound Imaging | November 13, 2019
November 13, 2019 – Mindray announced its partnership with...
Using artificial intelligence to predice risk of thyroid cancer on ultrasound.

Using artificial intelligence to predice risk of thyroid cancer on ultrasound.

News | Artificial Intelligence | November 06, 2019
November 6, 2019 — Thyroid nodules are small lumps that form within the thyroid gland and are quite common in the gen
Windsong Radiology Group

Windsong Radiology Group

Sponsored Content | Case Study | Contrast Media Injectors | October 30, 2019
Windsong Radiology Group is a New York-based radiolo
The Konica Minolta Sonimage HS1 hand-carried system is designed for point of care ultrasound (POCUS) use for an immediate, quick look inside the patient. POCUS systems from several vendors are seeing rapid growth.

The Konica Minolta Sonimage HS1 hand-carried system is designed for point of care ultrasound (POCUS) use for an immediate, quick look inside the patient. POCUS systems from several vendors are seeing rapid growth.

Feature | Ultrasound Imaging | October 24, 2019 | Joan Toth
With the miniaturization of technology, improved ease of use, lower system cost, increased portability, and greater
Exact Imaging Receives FDA 510(k) Clearance for Sterile Transperineal Needle Guide
Technology | Ultrasound Imaging | October 24, 2019
Exact Imaging received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Sterile Transperineal Needle...
The Revolution Apex intelligent computed tomography (CT) scanner

The Revolution Apex intelligent computed tomography (CT) scanner. Image courtesy of GE Healthcare.

News | RSNA | October 18, 2019
At the 2019 annual meeting of the Radiological Society of North America (RSNA 2019), Dec. 1-6 in Chicago, GE Healthcare...
Philips Partners With PURE on Tele-Ultrasound Program for Physicians in Rwanda
News | Ultrasound Imaging | October 09, 2019
Philips and non-profit organization PURE (Point-of-care Ultrasound in Resource-limited Environments) highlighted a tele...